Artykuły w czasopismach: „Interleukin-6”

1

&NA;. "Interleukin-3/interleukin-6." Reactions Weekly &NA;, no. 550 (May 1995): 11. http://dx.doi.org/10.2165/00128415-199505500-00035.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

&NA;. "Interleukin-6." Reactions Weekly &NA;, no. 570 (September 1995): 9. http://dx.doi.org/10.2165/00128415-199505700-00023.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Lotz, Martin. "Interleukin-6." Cancer Investigation 11, no. 6 (January 1993): 732–42. http://dx.doi.org/10.3109/07357909309046948.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

&NA;. "Interleukin 6." Inpharma Weekly &NA;, no. 877 (March 1993): 2. http://dx.doi.org/10.2165/00128413-199308770-00001.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

&NA;. "Interleukin 6." Reactions Weekly &NA;, no. 505 (June 1994): 8. http://dx.doi.org/10.2165/00128415-199405050-00037.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

&NA;. "Interleukin 6." Reactions Weekly &NA;, no. 531 (December 1994): 8. http://dx.doi.org/10.2165/00128415-199405310-00027.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Song, Mingchen, and John A. Kellum. "Interleukin-6." Critical Care Medicine 33, Suppl (December 2005): S463—S465. http://dx.doi.org/10.1097/01.ccm.0000186784.62662.a1.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

CASTELL, JOSé V., TILO ANDUS, DIETER KUNZ, and PETER C. HEINRICH. "Interleukin-6." Annals of the New York Academy of Sciences 557, no. 1 (June 28, 2008): 87–101. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24001.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

9

LEE, FRANK, CHOY-PIK CHIU, JANUSZ WIDEMAN, PHILLIP HODGKIN, SUSAN HUDAK, LOUISE TROUTT, THERESA NG, et al. "Interleukin-6." Annals of the New York Academy of Sciences 557, no. 1 (June 28, 2008): 215–29. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24015.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

CLARK, STEVEN C. "Interleukin-6." Annals of the New York Academy of Sciences 557, no. 1 (June 28, 2008): 438–43. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24036.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

11

Olencki, Thomas, James Finke, and Ronald M. Bukowski. "Interleukin-6." Clinical Immunotherapeutics 2, no. 4 (October 1994): 278–94. http://dx.doi.org/10.1007/bf03258528.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

12

Sin, Don D., and S. F. Paul Man. "Interleukin-6." Chest 133, no. 1 (January 2008): 4–6. http://dx.doi.org/10.1378/chest.07-2085.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

13

Delk, Nikki A., and Mary C. Farach-Carson. "Interleukin-6." Autophagy 8, no. 4 (April 2012): 650–63. http://dx.doi.org/10.4161/auto.19226.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

14

Matsuda, Tadashi, and Toshio Hirano. "Interleukin 6 (IL-6)." Biotherapy 2, no. 4 (October 1990): 363–73. http://dx.doi.org/10.1007/bf02170085.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

15

Annisa, Yuanita Anggreini1 GontarAlamsyah Siregar*2 &. Leonardo Basa Dairi3. "ASSOCIATION BETWEEN INTERLEUKIN 6 SERUM LEVEL AND NON-ALCOHOLIC FATTY LIVER DISEASE." INTERNATIONAL JOURNAL OF RESEARCH SCIENCE & MANAGEMENT 6, no. 7 (July 19, 2019): 11–16. https://doi.org/10.5281/zenodo.3342743.

Pełny tekst źródła

Streszczenie:

Background. Non-Alcoholic Fatty Liver Disease (NAFLD) emerged as a major health problem throughout the world and is increasing as the prevalence of obesity and diabetes continues to increase and is recognized as a major cause of liver disease-related morbidity and mortality. Adipokine is critically involved in healthy liver physiology and in the pathophysiology of acute and chronic liver disease as an intermediary for liver inflammation, liver cell death, cholestasis, and fibrosis. Interleukin-6 (IL-6) is one of adipokines widely studied recently. IL-6 showed improvement and played an important role in the pathogenesis of NAFLD. Aim. To determine association of serum Interleukin 6 level with NAFLD and other marker associate with NAFLD. Methods. Cross-sectional study of 30 consecutive NAFLD patients who came to Adam Malik General Hospital Medan and North Sumatra University Hospital in 2018. NAFLD was diagnosed by abdominal ultrasound. Complete blood count, blood sugar level, parameters of liver function, lipid profile and IL-6 were measured in each subject. Results. Of the 60 subjects, they are divided into 2 groups; 30 subjects in the NAFLD group and 30 subjects in the NAFLD group. The mean serum IL-6 level in the NAFLD group was 5.1 ± 2.87pg / ml and the control group was 1.9 ± 0.50pg / ml. Conclusion. There was a significantly higher difference in serum Interleukin 6 (IL-6) levels between the Non Alcoholic Fatty Liver Disease (NAFLD) group and the control group.

Style APA, Harvard, Vancouver, ISO itp.

16

Rivera-Chavez, Fernando A., Dixie L. Peters-Hybki, Robert C. Barber, and Grant E. O'Keefe. "Interleukin-6 Promoter Haplotypes and Interleukin-6 Cytokine Responses." Shock 20, no. 3 (September 2003): 218–23. http://dx.doi.org/10.1097/00024382-200309000-00004.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

17

Ridker, Paul M. "Targeting Interleukin-1 and Interleukin-6." Journal of the American College of Cardiology 76, no. 15 (October 2020): 1774–76. http://dx.doi.org/10.1016/j.jacc.2020.08.052.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

18

NORTHEMANN, WOLFGANG, TODD A. BFUCIAK, MASAHIRA HATTORI, and GEORG H. FEY. "Rat Interleukin-6." Annals of the New York Academy of Sciences 557, no. 1 (June 28, 2008): 536–39. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24057.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

19

Schneider, Kirsten, Reinhard Klaas, Bernd Kaspers, and Peter Staeheli. "Chicken interleukin-6." European Journal of Biochemistry 268, no. 15 (August 1, 2001): 4200–4206. http://dx.doi.org/10.1046/j.1432-1327.2001.02334.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

20

Tamura, T., N. Udagawa, N. Takahashi, C. Miyaura, S. Tanaka, Y. Yamada, Y. Koishihara, Y. Ohsugi, K. Kumaki, and T. Taga. "Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6." Proceedings of the National Academy of Sciences 90, no. 24 (December 15, 1993): 11924–28. http://dx.doi.org/10.1073/pnas.90.24.11924.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

21

Ogawa, Michio, Kiyoshi Sakamoto, Seiji Mita, Takatoshi Ishiko, and Saburo Hisano. "INTERLEUKIN-6 AND SOLUBLE INTERLEUKIN-6 RECEPTOR IN SURGICAL TRAUMA." Shock 4, Supplement (December 1995): 11. http://dx.doi.org/10.1097/00024382-199512001-00045.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

22

De Filippo, G., D. Rendina, F. Moccia, V. Rocco, and A. Campanozzi. "Interleukin-6, soluble interleukin-6 receptor/interleukin-6 complex and insulin resistance in obese children and adolescents." Journal of Endocrinological Investigation 38, no. 3 (September 23, 2014): 339–43. http://dx.doi.org/10.1007/s40618-014-0176-4.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

Oka, Masaaki, Hiroshi Kusanagi, Toshihiro Saeki, Norio Iizuka, Hiroto Hayashi, Akira Tangoku, Takuo Murakami, and Takashi Suzuki. "Interleukin-6 Production and Interleukin-6 Receptor Expression in Human Esophageal Cancer Cell Lines." Japanese Journal of Gastroenterological Surgery 26, no. 11 (1993): 2707. http://dx.doi.org/10.5833/jjgs.26.2707.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

24

Prens, Errol P., Klazina Benne, Jozef van Damme, Marleen Bakkus, Karin Brakel, Robbert Benner, and Theodoor van Joost. "Interleukin-1 and Interleukin-6 in Psoriasis." Journal of Investigative Dermatology 95, no. 6 (December 1990): S121—S124. http://dx.doi.org/10.1111/1523-1747.ep12874991.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

25

Bota, Rafaqat, and Mushtaq Ahmed. "The pathophysiological profile of interleukin-6 and anti-interleukin-6 antibody." El Mednifico Journal 1, no. 2 (July 6, 2013): 51. http://dx.doi.org/10.18035/emj.v1i2.26.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

26

Ridker, Paul M., and Manas Rane. "Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease." Circulation Research 128, no. 11 (May 28, 2021): 1728–46. http://dx.doi.org/10.1161/circresaha.121.319077.

Pełny tekst źródła

Streszczenie:

IL (interleukin)-6 is a pivotal cytokine of innate immunity, which enacts a broad set of physiological functions traditionally associated with host defense, immune cell regulation, proliferation, and differentiation. Following recognition of innate immune pathways leading from the NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inflammasome to IL-1 to IL-6 and on to the hepatically derived clinical biomarker CRP (C-reactive protein), an expanding literature has led to understanding of the proatherogenic role for IL-6 in cardiovascular disease and thus the potential for IL-6 inhibition as a novel method for vascular protection. In this review, we provide an overview of the mechanisms by which IL-6 signaling occurs and how that impacts upon pharmacological inhibition; describe murine models of IL-6 and atherogenesis; summarize human epidemiological data outlining the utility of IL-6 as a biomarker of vascular risk; outline genetic data suggesting a causal role for IL-6 in systemic atherothrombosis and aneurysm formation; and then detail the potential role of IL-6 inhibition in stable coronary disease, acute coronary syndromes, heart failure, and the atherothrombotic complications associated with chronic kidney disease and end-stage renal failure. Finally, we review anti-inflammatory and antithrombotic findings for ziltivekimab, a novel IL-6 ligand inhibitor being developed specifically for use in atherosclerotic disease and poised to be tested formally in a large-scale cardiovascular outcomes trial focused on individuals with chronic kidney disease and elevated levels of CRP, a population at high residual atherothrombotic risk, high residual inflammatory risk, and considerable unmet clinical need.

Style APA, Harvard, Vancouver, ISO itp.

27

Jucker, M., H. Abts, W. Li, R. Schindler, H. Merz, A. Gunther, C. von Kalle, M. Schaadt, T. Diamantstein, and AC Feller. "Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease." Blood 77, no. 11 (June 1, 1991): 2413–18. http://dx.doi.org/10.1182/blood.v77.11.2413.2413.

Pełny tekst źródła

Streszczenie:

Abstract Interleukin-6 (IL-6) is a multipotent lymphokine that can mediate differentiation of B cells into Ig-secreting cells, stimulate the growth of plasmacytomas, hybridomas, and T cells, and induce acute- phase proteins in liver cells. It has been suggested that IL-6 is involved in the pathogenesis of several diseases by autocrine or paracrine pathways. To examine whether IL-6 is possibly involved in the pathophysiology of Hodgkin's disease (HD), we analyzed the expression of IL-6 and IL-6 receptor mRNA and protein in cell lines and primary specimens from patients with HD. IL-6-specific transcripts were detected in three of six HD-derived cell lines by Northern blot analysis. In the culture supernatants of four HD-derived cell lines, IL- 6 was detected by radioimmunoassay. Biologic activity of IL-6 was confirmed by proliferation of an IL-6-dependent cell line. In situ hybridization experiments showed IL-6-specific transcripts in Hodgkin (H) and Reed-Sternberg (RS) cells in primary tissues of two patients. In addition, mRNAs specific for the IL-6 receptor were detected in five HD-derived cell lines. Immunostaining experiments showed expression of IL-6 receptor molecules on H and RS cells in 8 of 16 cases with HD. Thus, our data suggest that IL-6 might be involved in the pathophysiology of HD.

Style APA, Harvard, Vancouver, ISO itp.

28

Jucker, M., H. Abts, W. Li, R. Schindler, H. Merz, A. Gunther, C. von Kalle, M. Schaadt, T. Diamantstein, and AC Feller. "Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease." Blood 77, no. 11 (June 1, 1991): 2413–18. http://dx.doi.org/10.1182/blood.v77.11.2413.bloodjournal77112413.

Pełny tekst źródła

Streszczenie:

Interleukin-6 (IL-6) is a multipotent lymphokine that can mediate differentiation of B cells into Ig-secreting cells, stimulate the growth of plasmacytomas, hybridomas, and T cells, and induce acute- phase proteins in liver cells. It has been suggested that IL-6 is involved in the pathogenesis of several diseases by autocrine or paracrine pathways. To examine whether IL-6 is possibly involved in the pathophysiology of Hodgkin's disease (HD), we analyzed the expression of IL-6 and IL-6 receptor mRNA and protein in cell lines and primary specimens from patients with HD. IL-6-specific transcripts were detected in three of six HD-derived cell lines by Northern blot analysis. In the culture supernatants of four HD-derived cell lines, IL- 6 was detected by radioimmunoassay. Biologic activity of IL-6 was confirmed by proliferation of an IL-6-dependent cell line. In situ hybridization experiments showed IL-6-specific transcripts in Hodgkin (H) and Reed-Sternberg (RS) cells in primary tissues of two patients. In addition, mRNAs specific for the IL-6 receptor were detected in five HD-derived cell lines. Immunostaining experiments showed expression of IL-6 receptor molecules on H and RS cells in 8 of 16 cases with HD. Thus, our data suggest that IL-6 might be involved in the pathophysiology of HD.

Style APA, Harvard, Vancouver, ISO itp.

29

Plenz, Gabriele, Heike Eschert, Michael Erren, Thomas Wichter, Michael Böhm, Markus Flesch, Hans H. Scheld, and Mario C. Deng. "The interleukin-6/interleukin-6-receptorsystem is activated in donor hearts." Journal of the American College of Cardiology 39, no. 9 (May 2002): 1508–12. http://dx.doi.org/10.1016/s0735-1097(02)01791-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

30

Nancey, Stéphane, Nadim Hamzaoui, Driffa Moussata, Ivan Graber, Jacques Bienvenu, and Bernard Flourie. "Serum Interleukin-6, Soluble Interleukin-6 Receptor and Crohn’s Disease Activity." Digestive Diseases and Sciences 53, no. 1 (June 5, 2007): 242–47. http://dx.doi.org/10.1007/s10620-007-9849-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

31

Angelis, Pela, Simon Scharf, Alastair Mander, Frank Vajda, and Nicholas Christophidis. "Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease." Neuroscience Letters 244, no. 2 (March 1998): 106–8. http://dx.doi.org/10.1016/s0304-3940(98)00136-0.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

32

Rezai, Ali R., Ahmad Rezai, Otoniel Mart�nez-Maza, Meta Vander-Meyden, and Martin H. Weiss. "Interleukin-6 and interleukin-6 receptor gene expression in pituitary tumors." Journal of Neuro-Oncology 19, no. 2 (June 1994): 131–35. http://dx.doi.org/10.1007/bf01306454.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

33

MONTERO-JULIAN, F. A., E. GAUTHEROT, J. WIJDENES, B. KLEIN, and H. BRAILLY. "Pharmacokinetics of Interleukin-6 During Therapy with Anti-Interleukin-6 Monoclonal Antibodies: Enhanced Clearance of Interleukin-6 by a Combination of Three Anti-Interleukin-6 Antibodies." Journal of Interferon Research 14, no. 5 (October 1994): 301–2. http://dx.doi.org/10.1089/jir.1994.14.301.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

34

KENIS, G., C. TEUNISSEN, R. DEJONGH, E. BOSMANS, H. STEINBUSCH, and M. MAES. "STABILITY OF INTERLEUKIN 6, SOLUBLE INTERLEUKIN 6 RECEPTOR, INTERLEUKIN 10 AND CC16 IN HUMAN SERUM." Cytokine 19, no. 5 (September 2002): 228–35. http://dx.doi.org/10.1016/s1043-4666(02)91961-7.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

35

Kenis, Gunter, Charlotte Teunissen, Raf De Jongh, Eugène Bosmans, Harry Steinbusch, and Michael Maes. "STABILITY OF INTERLEUKIN 6, SOLUBLE INTERLEUKIN 6 RECEPTOR, INTERLEUKIN 10 AND CC16 IN HUMAN SERUM." Cytokine 19, no. 5 (September 2002): 228–35. http://dx.doi.org/10.1006/cyto.2002.1961.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

36

HIRANO, TOSHIO. "Interleukin 6 (IL-6) and disease." Japanese Journal of Clinical Immunology 13, no. 5 (1990): 444–45. http://dx.doi.org/10.2177/jsci.13.444.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

37

Van Wagoner, N. J., and E. N. Benveniste. "Interleukin-6 regulation in human astrocytes: Synergy between TNF-alpha, interleukin-6, and the soluble-interleukin-6 receptor-alpha." Journal of Neuroimmunology 90, no. 1 (September 1998): 53. http://dx.doi.org/10.1016/s0165-5728(98)91497-7.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

38

Abasova, Dunya, Sevda Kazimova, Nazrin Macidova, Telli Shirinova, and Shalala Babayeva. "STUDY OF STOKIN STATUS IN PATIENTS WITH TOXOPLASMOSIS." Annali d'Italia 50 (December 26, 2023): 17–19. https://doi.org/10.5281/zenodo.10432472.

Pełny tekst źródła

Streszczenie:

The problem of opportunistic infections is becoming an urgent problem of modern times is becoming, which is a constant increase in the number of people infected with HIV, it is related to the increase in aggressive treatment methods of oncopathologies. This infections Pathogens that can normally cause disease in healthy individuals caused by Up to 20 typical causative agents of opportunistic infections are known, and in modern infectious diseases this list is constantly growing. without symptoms: 60% - cytomegalovirus, 90% - first and second type herpavirus, 30% are toxoplasma carriers. During the research, 100 people infected with toxoplasmosis were studied. The research shows that during  the exacerbation of the disease, the level of cytokines increases in comparison to healthy people, year-6, year-10. Cytokine balance depends on the severity of the disease. The aim of the study is to study the level of production of the main cytokines (year-6, year-10) that help to study the functional activity of immunocompetent cells and the severity of the infectious process in patients infected with toxoplasma.

Style APA, Harvard, Vancouver, ISO itp.

39

Sajjad, Kathem Ashour, Abd Jabbar Al-Ammar Haider, and Hamza Sharif Yasmine. "Interleukin-6 Biomarker as Possible Predicator of Preeclampsia." Biomedicine and Chemical Sciences, no. 4 (September 30, 2022): 306–11. https://doi.org/10.48112/bcs.v1i4.303.

Pełny tekst źródła

Streszczenie:

Preeclampsia (PE) is a serious illness that can harm both mothers and unborn children and may even be fatal. It contributes significantly to maternal fatalities in underdeveloped countries. PE, which affects 2%–3% of women who are pregnant after 20 weeks of pregnancy, is marked by proteinuria and hypertension. PE is a significant condition that plays a significant role in maternal fatalities in underdeveloped countries and is a significant cause of death for both mothers and newborns. Each year, around 60,000 maternal fatalities occur in the world. Serum interleukin-6 (IL-6) was measured in pregnant women during the first trimester and second trimesters. IL-6 was necessary to establish serum biomarkers that can accurately predict the onset of preeclampsia. In a prospective cohort study that was conducted in the Obstetrics and Gynecology Department and Antenatal Care Unit at Maternity and Pediatrics Teaching Hospital in AL-Diwaniyah – Iraq, 160 pregnant patients between the years of 20 and 40 who were normotensive and had gestational ages of 10 to 13 weeks were included in this research between August 2021 and May 2022. Bioassays for IL-6 were conducted after blood samples were obtained. At the end of the study, it was confirmed that for women with pre-eclampsia (n = 33, 22.0%) and those women with no pre-eclampsia (n = 117, 78.0 %), there was no significant difference in the level between the preeclampsia and no preeclampsia group (p > 0.05).

Style APA, Harvard, Vancouver, ISO itp.

40

Hoejberg, Lise, Lars Bastholt, and Henrik Schmidt. "Interleukin-6 and melanoma." Melanoma Research 22, no. 5 (October 2012): 327–33. http://dx.doi.org/10.1097/cmr.0b013e3283543d72.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

41

Rose-John, Stefan. "Interleukin-6 Family Cytokines." Cold Spring Harbor Perspectives in Biology 10, no. 2 (June 15, 2017): a028415. http://dx.doi.org/10.1101/cshperspect.a028415.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

42

Tanaka, Toshio, Masashi Narazaki, and Tadamitsu Kishimoto. "Interleukin (IL-6) Immunotherapy." Cold Spring Harbor Perspectives in Biology 10, no. 8 (August 4, 2017): a028456. http://dx.doi.org/10.1101/cshperspect.a028456.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

43

Suzuki, Kenshi, Akiko Miyashita, Yasuyuki Inoue, Seiko Iki, Hidetoshi Enomoto, Yuji Takahashi, and Tamiko Takemura. "Interleukin-6-Producing Pheochromocytoma." Acta Haematologica 85, no. 4 (1991): 217–19. http://dx.doi.org/10.1159/000204897.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

44

Kerr, Ron, David Stirling, and Christopher A. Ludlam. "Interleukin 6 and Haemostasis." British Journal of Haematology 115, no. 1 (October 2001): 3–12. http://dx.doi.org/10.1046/j.1365-2141.2001.03061.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

45

Nagila, Amar, Khem Raj Paudel, and Bijay Subedi. "Interleukin-6 in Hypothyroidism." Journal of Manmohan Memorial Institute of Health Sciences 9, no. 2 (November 22, 2024): 27–29. http://dx.doi.org/10.3126/jmmihs.v9i2.71838.

Pełny tekst źródła

Streszczenie:

Background: Hypothyroidism means that the thyroid gland can’t produce enough thyroid hormones. Interleukin 6 (IL-6) a cytokine of innate immunity is a soluble mediator with a pleotropic effect on inflammation. Interleukin 6 test is helpful to study the hypothyroid status and to assess the adverse effects of hypothyroidism, was not studied in a tertiary care center in Pokhara, Nepal. The aim of this study is to determine the levels of interleukin 6 and to correlate with hypothyroidism. Methodology: This was a hospital based cross-sectional study on 100 hypothyroid patients where samples were collected by convenient sampling from patients visiting the Tertiary care Hospital in Pokhara, Nepal. Thyroid function tests fT3, fT4 and TSH were analyzed by Chemiluminiscence Immunoassay (CLIA) for hypothyroidism. Interleukin 6 test was estimated by Immunofluorescence Assay (IFA). Excel-2010 and SPSS V 16.0 were used for data analysis. Result: Among the total hypothyroid population, 83(83.0%) were subclinical and 17(17.0%) were overt cases. The 31(31.0%) of the total population has increased level of IL-6 and 69(69.0%) were normal. In this study, out of the 17% overt cases IL-6 was increased in 82.35 % cases and 17.65% of them found normal. In case of 83% subclinical hypothyroidism, IL-6 was increased in only 20.48% of cases and 79.52% of them found normal. There was a significant association between inflammatory status and hypothyroid status. IL-6 was significantly correlated with fT3 (r= -0.485, p<0.01fT4 (r= -0.521, p<0.01) and TSH (r= 0.547, p<0.01). Conclusion: This study suggests that hypothyroid patients may have increased level of Interleukin 6. The frequency of inflammatory cases and severity of inflammation have been increased when cases worsen from subclinical to overt. Therefore, hypothyroidism must be treated early to avoid the consequences of inflammation. Keywords: Hypothyroidism, Interleukin-6, fT3, fT4

Style APA, Harvard, Vancouver, ISO itp.

46

Sehgal, Pravinkumar B. "Interleukin-6: Molecular Pathophysiology." Journal of Investigative Dermatology 94, no. 6 (June 1990): s2—s6. http://dx.doi.org/10.1111/1523-1747.ep12874963.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

47

Van Snick, Jacques. "Interleukin-6: An Overview." Annual Review of Immunology 8, no. 1 (April 1990): 253–78. http://dx.doi.org/10.1146/annurev.iy.08.040190.001345.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

48

Pedersen, Bente Klarlund, Adam Steensberg, and Peter Schjerling. "Exercise and interleukin-6." Current Opinion in Hematology 8, no. 3 (May 2001): 137–41. http://dx.doi.org/10.1097/00062752-200105000-00002.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

49

Patarca, Roberto, and Mary Ann Fletcher. "Interleukin-6 and Disease." Journal of Chronic Fatigue Syndrome 4, no. 1 (January 1998): 53–69. http://dx.doi.org/10.1300/j092v04n01_07.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

50

SEHGAL, PRAVIN B., LING WANG, RAVI RAYANADE, HENG PAN, and LOLA MARGULIES. "Interleukin-6-Type Cytokinesa." Annals of the New York Academy of Sciences 762, no. 1 (December 17, 2006): 1–14. http://dx.doi.org/10.1111/j.1749-6632.1995.tb32309.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Artykuły w czasopismach na temat „Interleukin-6”

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych